Multiple Sclerosis clinical trials at UCLA

3 in progress, 1 open to eligible people

Showing trials for

  • Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    open to eligible people ages 18-60

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

    Torrance, California and other locations

  • Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

    Sorry, in progress, not accepting new patients

    This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

    Torrance, California and other locations

  • Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

    Sorry, in progress, not accepting new patients

    A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.

    Torrance, California and other locations

Last updated: